Biden’s diagnosis is unfortunate but—statistically—not surprising Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule

Unfold AI, an AI prostate cancer mapping and clinical decision support platform, is now included in Medicare’s Physician Fee Schedules across the West Coast and Mountain West regions. The regional expansion of Medicare payment for the tool gives urologists and care teams clearer reimbursement pathways in physician office settings, an area that has historically lagged behind hospital outpatient settings for emerging technologies.

May 01, 2026

Vol.52 No.17

Clinical Roundup

Small molecule inhibitor blocks prostate cancer bone metastasis

Findings out of VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine, published in Pharmacological Research, show that a targeted small molecule inhibitor, IVMT-Rx-4, may prevent prostate tumors from spreading to an advanced and incurable stage in the bones.

April 03, 2026

Vol.52 No.13

Clinical Roundup

Talzenna + Xtandi significantly improves radiographic PFS in metastatic prostate cancer

Pfizer announced positive topline results from the phase III TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, in people with homologous recombination repair gene-mutated metastatic castration-sensitive prostate cancer, also known as metastatic hormone-sensitive prostate cancer.

March 27, 2026

Vol.52 No.12

Clinical Roundup

Researchers “turbocharge” immune cells to attack prostate cancer

A team of researchers engineered a new class of “turbocharged” T cells that may be stronger, longer-lasting, and more precise at killing prostate cancer cells. The approach represents a step toward developing safer, more effective T-cell therapies for prostate cancer and could potentially be adapted to treat a wide range of other tumors.

March 27, 2026

Vol.52 No.12

Clinical Roundup

Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, UCLA-led study finds

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most men with prostate cancer, especially for those with very low PSA levels before treatment.

March 06, 2026

Vol.52 No.09

Clinical Roundup

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

Pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment, according to a Mayo Clinic-led study.

February 27, 2026

Vol.52 No.08

Biden’s diagnosis is unfortunate but—statistically—not surprising

Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

YOU MAY BE INTERESTED IN

Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule

Small molecule inhibitor blocks prostate cancer bone metastasis

Talzenna + Xtandi significantly improves radiographic PFS in metastatic prostate cancer

Researchers “turbocharge” immune cells to attack prostate cancer

Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, UCLA-led study finds

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

Renew today!

Subscriber content

Never miss an issue!

Login